How can you be a successful healthcare analyst without having a medical background?

I am currently a college student and have had dreams of pursuing a career at a L/S equity hedge fund for awhile now. I am a firm believer in that you have to be truly interested in the sector you are covering, or else the hours and stress will just be miserable. I have recently become interested in the healthcare sector after reading about all the people who have crushed it this year in biotech, and this led me to wonder:

Is it possible for a non-medical background person to become a successful analyst in healthcare? The reason I ask is because when it comes down to really understanding business models, a finance major that then went on to do the 2+2 path will never understand a biopharma or a biotech company better than someone who went to medical school or was on track to being a doctor. However, I know that some of the most successful PM's in the industry do not have medical backgrounds, so I am curious how they learn to think about these businesses without having that extensive knowledge. 

TLDR: Am I wrong for saying that any MD candidate who ultimately wants to go into finance will always be able to understand the healthcare companies better than those who did banking after majoring in finance? If true, how do non-medical background people succeed in healthcare investing? 
 

Thanks everyone and happy holidays! 

14 Comments
 

Yes u can be better than medical background guy but goodluck getting credit for it.

You’re also overestimating how much knowledge ppl in med school have. It’s in inch deep and a mile wide. Anyone with a basic understanding of science can pick up the pathophys of a disease and the major drug classes in under 2 days.

Not saying this is all there is to m la of said dx but med students (medical doctors as well) typically only know this level of understanding unless there disease)

 
Most Helpful

I’ll answer this seriously. Yes, it’s possible, but it’s not as common. There’s a bigger technical moat the closer you get to pure trial analysis. Why? It’s a complex, data driven exercise. You usually have a set of precedents to compare an asset to, and you need to probability adjust for the data you have, the data you don’t, and the data you could never have before a catalyst to set expectations. That work is usually dense, and someone who hasn’t spent significant time reading, writing, or debating scientific literature will likely find it daunting.

That said, it really is still a data exercise. If you’re a voracious reader and comfortable building a knowledge base in something unfamiliar, you can absolutely succeed.

Will it take more time than for someone who doesn’t need to learn a disease pathway before understanding how a drug could work? Yes. But plenty of PhDs/MD's who succeed in this job do so less because of the degree and more because they’ve developed strong self directed learning habits and are willing to engage. In my opinion, a pharmacokinetics and pharmacodynamics textbook, high school level statistics, and a lot of will can take you very far.

Getting someone to give you a shot is a different story, and unfortunately not well within your control. The way I see this most often occur is those with undergrad degrees in a STEM field are usually given a chance as juniors to model for those running risk, they either graduate into more responsibility or are seen as permanent support before bouncing around/pivoting into something else.

 

 

Magnam eveniet molestias qui eum nihil voluptatibus dolore. Blanditiis non aut sed necessitatibus. Aut iure minus culpa impedit et corporis. Quas autem dolorem impedit qui dignissimos modi nihil et.

Repellat consequatur illo est et minus. Aliquam dolores aspernatur tempora necessitatibus ratione ut dignissimos. Iste fuga odit eum repellat exercitationem ipsum. Eius excepturi impedit officiis. Quasi provident maiores fugit ea animi. Vel ad qui impedit ullam. Magni sunt neque enim voluptas quas.

Ullam vel cupiditate adipisci. Aspernatur laboriosam hic placeat quaerat. Perferendis quasi velit quidem dolorem magnam. Consequuntur laudantium incidunt totam unde at.

Maxime rerum maiores eum quia. Dolorem est fugiat et dicta aperiam sed voluptas sapiente. Inventore consequatur fugit eum placeat delectus ut.

Career Advancement Opportunities

August 2026 Hedge Fund

  • Point72 99.0%
  • D.E. Shaw 98.0%
  • Citadel Investment Group 97.0%
  • AQR Capital Management 96.0%
  • Magnetar Capital 95.0%

Overall Employee Satisfaction

August 2026 Hedge Fund

  • Magnetar Capital 99.0%
  • D.E. Shaw 98.0%
  • Blackstone Group 97.0%
  • Citadel Investment Group 96.0%
  • Two Sigma Investments 94.9%

Professional Growth Opportunities

August 2026 Hedge Fund

  • AQR Capital Management 99.0%
  • Point72 98.0%
  • D.E. Shaw 97.1%
  • Citadel Investment Group 96.1%
  • Magnetar Capital 95.1%

Total Avg Compensation

August 2026 Hedge Fund

  • Portfolio Manager (9) $1,648
  • Vice President (27) $464
  • Director/MD (11) $372
  • NA (9) $320
  • Engineer/Quant (83) $287
  • 3rd+ Year Associate (26) $284
  • Manager (4) $282
  • 2nd Year Associate (32) $253
  • 1st Year Associate (76) $193
  • Analysts (233) $178
  • Intern/Summer Associate (29) $145
  • Junior Trader (5) $102
  • Intern/Summer Analyst (276) $95
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
Secyh62's picture
Secyh62
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
CompBanker's picture
CompBanker
98.9
6
DrApeman's picture
DrApeman
98.9
7
dosk17's picture
dosk17
98.9
8
GameTheory's picture
GameTheory
98.9
9
Betsy Massar's picture
Betsy Massar
98.9
10
Linda Abraham's picture
Linda Abraham
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”